Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs SNX 5422 (Primary)
- Indications Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 27 Jul 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 27 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.